โ† All deals

Pelthos Therapeutics Inc.

PharmaceuticalsPharmaceuticalsBiopharmaceuticalTherapeutics
๐Ÿ“ Durham, NC, United Statesโ€ข Founded 2024
StreetZero Signal 70
Be the first to signal interest

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. is a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs. Its lead product ZELSUVMI is the first and only FDA-approved prescription medication for Molluscum contagiosum that can be administered at home. The company also plans to launch Xepi and Xeglyze. Headquartered in Durham, NC, it was founded in 2024 and operates as a privately held B2B pharmaceutical manufacturer.

LATEST FUNDINGPrivate Placement
$57.5M
Announced 2026-11-16
TOTAL RAISED$98M
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Pelthos Therapeutics Inc..

Free plan includes 3 full deal profiles every month.

Key highlights

  • Secured up to $50M senior secured term loan facility from Horizon Technology Finance with $30M initially funded.
  • Completed merger with Channel Therapeutics supported by $50M equity raise led by Murchinson.
  • Commercializing ZELSUVMI, the first at-home prescription treatment for Molluscum contagiosum.
  • Ligand Pharmaceuticals entitled to 13% royalty on worldwide ZELSUVMI sales.
  • Total funding reached $98M across three rounds including Post-IPO debt.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account